Commercial Insight: HIV - Reshaping Treatment Paradigms

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-07-11

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.


Scope

  • In-depth analysis of the current HIV market across the major US and EU markets
  • Thorough assessment of underlying commercial and clinical factors shaping the antiretroviral market
  • Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets
  • Case study analysis of the entry inhibitor class focusing on the competitive environment and critical success factors


    • Report Highlights
    By 2016 the HIV market is forecasted to grow to $11.5 billion. This growth will be driven mainly by the increase in numbers of patients accessing treatments as well as the launch of several new drugs and drug classes

    The availability of several simple, once-daily treatments such as fixed dose combinations and once daily protease inhibitors has intensified the competition within the respective classes. Adherence to therapy is consequently expected to improve leading to a decline in the number of patients entering late-stage therapy.

    The anticipated launches of pipeline antiretrovirals such as CCR5 inhibitors, integrase inhibitors and others, which demonstrate novel activity and efficacy against resistant mutants, will not only offer more variety to patients but will increase the overall value of the market.


    Reasons to Purchase

  • Understand the constantly evolving market dynamics of antiretroviral drugs
  • Understand the impact of pending patent expiries and generic incursion on the ARV market, including product-specific case studies
  • Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2006 to 2016.

    • Table of Contents

    Other users found this report page using the following search terms: hiv ccr5 integrase haart hiv reshaping paradigms treatment insight commercial risks market

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.